Candriam SCA’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-56,282
| Closed | -$3.59M | – | 719 |
|
|
2025
Q1 | $3.59M | Sell |
56,282
-357
| -0.6% | -$37.6K | 0.02% | 396 |
|
|
2024
Q4 | $6.89M | Sell |
56,639
-2,869
| -5% | -$352K | 0.04% | 312 |
|
|
2024
Q3 | $7.43M | Sell |
59,508
-69,492
| -54% | -$9.61M | 0.04% | 302 |
|
|
2024
Q2 | $20.4M | Sell |
129,000
-22,000
| -15% | -$2.83M | 0.12% | 165 |
|
|
2024
Q1 | $19.5M | Sell |
151,000
-31,445
| -17% | -$3.85M | 0.13% | 169 |
|
|
2023
Q4 | $17.6M | Buy |
182,445
+46,736
| +34% | +$4.48M | 0.12% | 174 |
|
|
2023
Q3 | $16.5M | Buy |
135,709
+35,709
| +36% | +$4.04M | 0.12% | 168 |
|
|
2023
Q2 | $11.5M | Sell |
100,000
-22,194
| -18% | -$2.86M | 0.08% | 230 |
|
|
2023
Q1 | $15.5M | Buy |
122,194
+27,050
| +28% | +$3.51M | 0.11% | 199 |
|
|
2022
Q4 | $12.3M | Buy |
+95,144
| New | +$11M | 0.08% | 231 |
|
|
2021
Q2 | – | Sell |
-164,008
| Closed | -$26.9M | – | 938 |
|
|
2021
Q1 | $26.9M | Hold |
164,008
| – | – | 0.22% | 119 |
|
|
2020
Q4 | $28M | Sell |
164,008
-10,821
| -6% | -$1.6M | 0.22% | 119 |
|
|
2020
Q3 | $24.6M | Hold |
174,829
| – | – | 0.23% | 105 |
|
|
2020
Q2 | $28M | Buy |
174,829
+9,729
| +6% | +$1.32M | 0.3% | 86 |
|
|
2020
Q1 | $20.8M | Hold |
165,100
| – | – | 0.23% | 92 |
|
|
2019
Q4 | $21.3M | Sell |
165,100
-27,500
| -14% | -$2.78M | 0.23% | 92 |
|
|
2019
Q3 | $14.5M | Hold |
192,600
| – | – | 0.19% | 124 |
|
|
2019
Q2 | $29.1M | Hold |
192,600
| – | – | 0.36% | 54 |
|
|
2019
Q1 | $23M | Buy |
192,600
+66,500
| +53% | +$8.55M | 0.29% | 73 |
|
|
2018
Q4 | $13.8M | Buy |
126,100
+3,000
| +2% | +$375K | 0.21% | 112 |
|
|
2018
Q3 | $19.9M | Buy |
123,100
+64,100
| +109% | +$8.76M | 0.26% | 88 |
|
|
2018
Q2 | $7.8M | Buy |
59,000
+11,000
| +23% | +$1.04M | 0.12% | 209 |
|
|
2018
Q1 | $3.56M | Buy |
48,000
+6,000
| +14% | +$400K | 0.06% | 349 |
|
|
2017
Q4 | $2.34M | Buy |
+42,000
| New | +$2.22M | 0.04% | 426 |
|
|
2016
Q2 | – | Sell |
-43,000
| Closed | -$835K | – | 675 |
|
|
2016
Q1 | $835K | Buy |
43,000
+23,000
| +115% | +$402K | 0.02% | 456 |
|
|
2015
Q4 | $772K | Sell |
20,000
-21,800
| -52% | -$707K | 0.02% | 417 |
|
|
2015
Q3 | $1.34M | Buy |
41,800
+1,800
| +5% | +$61.1K | 0.03% | 396 |
|
|
2015
Q2 | $1.22M | Sell |
40,000
-30,000
| -43% | -$613K | 0.03% | 421 |
|
|
2015
Q1 | $930K | Buy |
70,000
+10,000
| +17% | +$133K | 0.02% | 458 |
|
|
2014
Q4 | $868K | Buy |
+60,000
| New | +$1.02M | 0.02% | 455 |
|
Other funds holding SRPT
EAM
Candriam SCA's SRPT Position: Q2 2025 in Review
Candriam SCA sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 56,282 shares — an estimated $3.59M sold.
Candriam SCA first reported a position in SRPT in Q4 2014 and held it in 30 quarters. The position peaked at $29.1M in Q2 2019. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.
- Candriam SCA reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
- Candriam SCA sold 56,282 Sarepta Therapeutics shares in Q2 2025, an estimated $3.59M.
- Candriam SCA first reported a position in Sarepta Therapeutics in Q4 2014 and held it in 30 quarters.
- Candriam SCA's Sarepta Therapeutics position peaked at $29.1M in Q2 2019.
- 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.
Based on Candriam SCA's 13F filing for Q2 2025, filed 8 Aug 2025.